Valuation Gilead Sciences, Inc. Mexican S.E.

Stocks

End-of-day quote Mexican S.E. Other stock markets 01/07/2026			5-day change	1st Jan Change
2,217.67 ^MXN	+0.63%		+0.63%	-0.21%

07-02	Trial for Bundibugyo Ebola treatment starts in DRC, WHO says	RE
06-30	Africa CDC seeks $18 million in urgent support for Ebola drug trials in DRC	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	162,981	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	7.03%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	172,549	162,884	152,574
Change	-	6.74%	-6.21%	11.1%	28.63%	1.75%	-5.6%	-6.33%
P/E	14.7x	23.6x	18x	243x	18.1x	-46.9x	17.1x	15.9x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.32x	6.6x	5.38x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.99x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.35x	5.04x	4.78x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.66x	5.03x	4.47x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	31.5x	9.14x	8.4x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	63.2x	10.5x	9.2x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	170x	12.3x	11x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.59%	8.13%	9.11%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.246	3.316	2.959
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.47%	2.53%	2.25%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.801	7.669	8.282
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-116%	43.2%	35.7%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,465	32,359	34,108
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,484	17,828	18,171
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,729	15,524	16,583
Net income ¹	6,225	4,592	5,665	480	8,510	-3,373	9,548	10,218
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,568	-96.43	-10,407
Reference price ²	72.61	85.85	81.01	92.37	122.74	131.27	131.27	131.27
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	01/02/22	02/02/23	06/02/24	11/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	35.49x	12.89x	26.26x	0.56%	1,082B
JOHNSON & JOHNSON	28.11x	6.46x	17.57x	2.03%	633B
ABBVIE INC.	32.2x	7.69x	15.73x	2.65%	461B
ROCHE HOLDING AG	18.2x	4.52x	11.11x	2.93%	339B
ASTRAZENECA PLC	24.21x	5.06x	14.18x	1.72%	301B
NOVARTIS AG	22.23x	5.7x	13.76x	2.76%	292B
NOVO NORDISK A/S	14.65x	5.43x	11.14x	3.42%	225B
AMGEN INC.	24.39x	6.45x	11.36x	2.7%	202B
PFIZER INC.	11.37x	3.03x	7.37x	7.2%	139B
Average	23.43x	6.36x	14.28x	2.89%	408.37B
Weighted average by Cap.	27.43x	7.96x	17.60x	2.11%